IL-13 Antibody (A-9): sc-393365

IL-13 Antibody (A-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects IL-13 protein of mouse origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IL-13 (A-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Interleukin-13, or IL-13, is a pleiotropic cytokine that plays a crucial role in immune regulation and inflammation, exhibiting approximately 30% sequence identity with IL-4 and sharing many biological activities. IL-13 is primarily secreted by activated T lymphocytes and significantly influences monocytes, macrophages, and B cells by upregulating CD23 and major histocompatibility complex proteins while downregulating CD14. IL-13 is involved in inhibiting proinflammatory cytokines and chemokines from activated monocytes, as well as stimulating IgE expression on activated B cells, making IL-13 a key player in allergic responses and asthma. IL-13′s structure includes five cysteine residues, which are essential for stability and function, and multiple N-linked glycosylation sites that are critical for biological activity and interaction with receptors. IL-13 cDNA encodes a 131 amino acid precursor that includes a 20 amino acid signal peptide, which is cleaved to produce the mature protein, highlighting the importance of post-translational modifications in functional regulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IL-13 Antibody (A-9) References:

1. IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse.  |  Zhou, W., et al. 2006. Microbes Infect. 8: 2880-9. PMID: 17110149
2. Specific inhibition of interleukin-13 activity by a recombinant human single-chain immunoglobulin domain directed against the IL-13 receptor alpha1 chain.  |  Knackmuss, S., et al. 2007. Biol Chem. 388: 325-30. PMID: 17338640
3. Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells.  |  Suresh, V., et al. 2007. Am J Respir Cell Mol Biol. 37: 97-104. PMID: 17347445
4. A protective role for IL-13 receptor α 1 in bleomycin-induced pulmonary injury and repair.  |  Karo-Atar, D., et al. 2016. Mucosal Immunol. 9: 240-53. PMID: 26153764
5. Basophils balance healing after myocardial infarction via IL-4/IL-13.  |  Sicklinger, F., et al. 2021. J Clin Invest. 131: PMID: 34196299
6. IL-13 down-regulates CD14 expression and TNF-alpha secretion in normal human monocytes.  |  Cosentino, G., et al. 1995. J Immunol. 155: 3145-51. PMID: 7545713
7. IL-13 results in differential regulation of the complement proteins C3 and factor B in tumour necrosis factor (TNF)-stimulated fibroblasts.  |  Katz, Y., et al. 1995. Clin Exp Immunol. 101: 150-6. PMID: 7621584
8. Immunoregulatory properties of IL-13: its potential role in atopic disease.  |  de Vries, JE. and Zurawski, G. 1995. Int Arch Allergy Immunol. 106: 175-9. PMID: 7888780
9. Interleukin 13 elicits a subset of the activities of its close relative interleukin 4.  |  Zurawski, G. and de Vries, JE. 1994. Stem Cells. 12: 169-74. PMID: 7911047
10. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses.  |  Minty, A., et al. 1993. Nature. 362: 248-50. PMID: 8096327
11. Modulation of expression of the anti-inflammatory cytokines interleukin-13 and interleukin-10 by interleukin-3.  |  Marietta, EV., et al. 1996. Eur J Immunol. 26: 49-56. PMID: 8566083
12. Interleukin 13 suppresses cytokine production and stimulates the production of 15-HETE in PBMC. A comparison between IL-4 and IL-13.  |  Deleuran, B., et al. 1995. Cytokine. 7: 319-24. PMID: 8589261

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IL-13 Antibody (A-9) has 12 citations in a variety of scientific publications.

Primary antibodies like Anti-IL-13 Antibody (A-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IL-13 Antibody (A-9) Specifications

Alternate Product Name: IL-13

Product Clone Name: A-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 87-112

Epitope Target: IL-13

Epitope Species: mouse

Product Reactivity/Detection: IL-13

Species Reactivity/Detection: mouse

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 12 citations in various scientific publications

Available Conjugates/Forms for IL-13 Antibody (A-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin